BHP Group: BHP
Investors have ignored the mining companies for more than a decade as people wanted to focus on the GoGo tech stocks. People did not care much about value stocks, which…
Fed Day
The Fed is meeting to discuss the next steps in monetary policy. The consensus is that they will raise the Target Fed Funds Rate by 0.25%. This will bring the…
Exxon Update: XOM
On 8-May-2023, we discussed a buy-write, aka covered call strategy applied to Exxon Mobile stock. This article is for paid members - please login or subscribe for access.
Discover Financial Service: DFS
Discover Financial Services (DFS) reported Q2 2023 earnings last week, and traders were unimpressed. Traders took the stock down $19.40 a share or 15.9%. Our question is, "Were the results…
Royal Caribbean Cruises Ltd, Cruisin’ for a Bruisin’?: RCL
Few industries were hit harder than the cruise industry during the C-19 lockdown. The reason for this is clear. This article is for paid members - please login or subscribe…
STMicroelectronics NV: STM
Finding an un devalued stock in the tech space is becoming more challenging. Investors have bid up the price of software and device companies assuming they will perform to perfection.…
Microstrategy 2nd Update: MSTR
One of the biggest, if not the biggest winner we have ever discussed here at theOptionsEdge.Com, is Microstrategy, the business intelligence software company and largest publicly traded bitcoin holder. This…
Is Estee Lauder Companies Looking Pretty?: EL
Estee Lauder is one of the big success stories in the Beauty Industry. It has a highly recognized brand name and has historically captured a price premium for the high-quality…
T-Mobile: TMUS
T-Mobile stock was the big winner in the wireless wars between ATT, Verison & T-Mobile. Will it continue to be a winner, or is growth through acquisition and market-share accretion…
Abbvie Inc.: ABBV
Companies in the biopharmaceutical are challenging to get your arms around. The development of pharmaceutical treatments is highly technical and requires scientific insight. Further, developing these therapies is expensive and…